Literature DB >> 9332461

Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.

C B Jones1, M K Clements, S Wasi, S S Daoud.   

Abstract

PURPOSE: To assess parameters that might determine resistance to the topoisomerase I inhibitor, camptothecin (CPT), the sensitivities of three established human breast cancer cell lines (ER-) and of normal bovine endothelial cells to CPT in the free form and incorporated into liposomes (LCPT), were contrasted with topoisomerase I (topo I) content and activity, and with cell cycle response to CPT treatment.
METHODS: Drug sensitivities were determined using the tetrazolium dye assay and by 3H-thymidine incorporation. Topo I levels were determined by Western blot analysis, and catalytic activity was determined with a plasmid relaxation assay, using nuclear protein from each cell line. CPT stabilization of cleavable complexes in nuclear extracts was determined using a labeled oligonucleotide with a specific topo I cleavage site. Cell cycle response to CPT was determined by flow cytometric analysis of propidium iodide-stained nuclei.
RESULTS: CPT was extremely potent against MDA-MB-157 cells with an IC50 value of 7 nM compared with IC50 values of 150 nM for GI 101A and 250 nM for MDA-MB-231 cells. In contrast, CPT inhibited the incorporation of 3H-thymidine at very low doses in GI 101A and MDA-MB-231 cells with IC50 values of 9 nM and 5 nM, respectively; while MDA-MB-157 cells did not stop incorporating 3H-thymidine until very high doses (500 nM) of CPT were used. When incorporated into multilamellar liposomes (LCPT), CPT retained its potency, with IC50 values similar to that of the free drug. No correlation was found between CPT-induced cytotoxicity and any of the topo I parameters determined. Cell cycle analysis, however, showed an accumulation of cells in G2/M phase after 24 h treatment with low doses (5 nM) of CPT in only GI 101A and MDA-MB-231 cells with no arrest in normal endothelial or MDA-MB-157 cells. At higher doses (50 nM), however, a dramatic accumulation of cells in the S phase was observed in MDA-MB-157, MDA-MB-231 and GI 101A cells. In contrast, a G2/M phase block was seen with the normal bovine endothelial cells using the higher doses of CPT.
CONCLUSIONS: The results suggest that cell cycle regulation plays an important role in determining the effect of CPT on malignant and normal cells. The possible mechanisms explaining the sensitivities of the two cellular compartments to the action of CPT are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332461     DOI: 10.1007/s002800050690

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.

Authors:  Kathryn M Camacho; Sunny Kumar; Stefano Menegatti; Douglas R Vogus; Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2015-04-25       Impact factor: 9.776

2.  Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus.

Authors:  Lorenzo González-Molleda; Yan Wang; Yan Yuan
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

3.  Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.

Authors:  M E Proulx; A Désormeaux; J F Marquis; M Olivier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.

Authors:  Abdur Rehman; Manpreet S Chahal; Xiaoting Tang; James E Bruce; Yves Pommier; Sayed S Daoud
Journal:  Breast Cancer Res       Date:  2005-07-27       Impact factor: 6.466

5.  Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes.

Authors:  Sieun Chae; Dahee Kim; Kyung-Jin Lee; Dasol Lee; Young-O Kim; Yong Chae Jung; Sang Dal Rhee; Kwang Rok Kim; Jeong-O Lee; Sunjoo Ahn; Byumseok Koh
Journal:  ACS Omega       Date:  2018-06-01

Review 6.  Narrative review of gene modification: applications in three-dimensional (3D) bioprinting.

Authors:  Bowen Fu; Jianlin Shen; Yu Chen; Yanjiao Wu; Heshi Zhang; Huan Liu; Wenhua Huang
Journal:  Ann Transl Med       Date:  2021-10

7.  Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

Authors:  Andrea Worschech; Nanhai Chen; Yong A Yu; Qian Zhang; Zoltan Pos; Stephanie Weibel; Viktoria Raab; Marianna Sabatino; Alessandro Monaco; Hui Liu; Vladia Monsurró; R Mark Buller; David F Stroncek; Ena Wang; Aladar A Szalay; Francesco M Marincola
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

8.  Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin.

Authors:  Jan Simák; Karel Holada; Jaroslav G Vostal
Journal:  BMC Cell Biol       Date:  2002-05-28       Impact factor: 4.241

9.  A Lamin-Binding Ligand Inhibits Homologous Recombination Repair of DNA Double-Strand Breaks.

Authors:  Bingbing X Li; Jingjin Chen; Bo Chao; Yixian Zheng; Xiangshu Xiao
Journal:  ACS Cent Sci       Date:  2018-09-17       Impact factor: 14.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.